Skip to main content
. Author manuscript; available in PMC: 2022 Feb 10.
Published in final edited form as: J Control Release. 2020 Dec 13;330:173–184. doi: 10.1016/j.jconrel.2020.12.007

Fig. 3. In vitro binding affinity, specificity, and internalization studies of the 6WJ RNA nanoparticles harboring hepatocyte targeting ligands.

Fig. 3.

A. Binding assay of 6WJ/HTL & 6WJ/HTL/PTX/miR122 nanoparticles to ASGP-R positive HepG2 cells and ASGP-R negative KB cells as negative control. B. Effect of concentration on binding affinity of 6WJ (red) and 6WJ/HTL nanoparticles (blue) to ASGP-R positive HepG2 cells. C. Competitive assay of free galactosamine with 6WJ/HTL (blue) and 6WJ (red) nanoparticle against ASGP-R positive HepG2, respectively. D. Confocal imaging showing the internalization of 6WJ and 6WJ/HTL/PTX/miR122 nanoparticles into HepG2 cells, nuclei (blue), cytoskeleton (green) and RNA nanoparticles (red), 100 μm for original images, and 20 μm for magnified images.